61 results on '"Mondelli, Mario U."'
Search Results
2. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
3. Does co-administration of vaccines interfere with immune responses? The jury is still out.
4. Real-life lack of evidence of viable SARS-CoV-2 transmission via inanimate surfaces: The SURFACE study.
5. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
6. Acute hepatitis C: diagnosis and management
7. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients
8. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial
9. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients
10. Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein
11. Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?
12. The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort.
13. Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It Hot.
14. Neonatal blood microtransfusions and hepatitis C virus infection
15. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy.
16. Acute severe hepatitis of unknown aetiology in children: a new non-A–E hepatitis virus on horizon?
17. Do Liver Mucosa-Associated Invariant T Cells Delay Hepatitis C Progression, or Are They Innocent Bystanders?
18. Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
19. Management of infections in cirrhotic patients: Report of a Consensus Conference.
20. Multifaceted functions of B cells in chronic hepatitis C virus infection
21. Low risk of SARS-CoV-2 transmission by fomites in real-life conditions.
22. RE: Effects of Long-Term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
23. NKG2D and its ligands: Key to immunotherapy of liver cancer?
24. Eltrombopag: An effective remedy for thrombocytopaenia?
25. Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts?
26. Elimination of hepatitis C in Europe: can WHO targets be achieved?
27. HBV genotype must be included in treatment algorithm
28. Natural Killer Cell Functional Dichotomy in Chronic Hepatitis B and Chronic Hepatitis C Virus Infections.
29. Foreword
30. Properties of a human monoclonal antibody specific for the NS4 region of hepatitis C virus
31. Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications
32. Is there a role for immune responses in the pathogenesis of hepatitis C?
33. HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection
34. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C
35. Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk
36. Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies.
37. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis
38. Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells.
39. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
40. Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7.
41. Optimization for the detection of hepatitis C virus antigens in the liver
42. Molecular epidemiology of hepatitis C virus infection among intravenous drug users
43. Albert Geerts One of the “young boys”
44. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review.
45. Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference.
46. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
47. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection
48. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections
49. Is response to antiviral treatment influenced by hepatitis B virus genotype?
50. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.